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Abstract
Background: Accurate determination of coagulation factor VIII activity (FVIII:C) is 
essential for effective and safe FVIII replacement therapy. FVIII:C can be measured 
by one‐stage and chromogenic substrate assays (OSAs and CSAs, respectively); how-
ever, there is significant interlaboratory and interassay variability.
Aims: This international comparative field study characterized the behaviour of OSAs 
and CSAs used in routine laboratory practice to measure the activity of Nuwiq® 
(human‐cl rhFVIII, simoctocog alfa), a fourth‐generation recombinant human FVIII 
produced in a human cell line.
Methods: FVIII‐deficient plasma was spiked with Nuwiq® or Advate® at 1, 5, 30 and 
100 international units (IU)/dL. Participating laboratories analysed the samples using 
their routine procedures and equipment. Accuracy, inter‐ and intralaboratory varia-
tion, CSA:OSA ratio and the impact of different OSA and CSA reagents were assessed.
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1  | INTRODUC TION
The mainstay of current haemophilia A treatment is coagulation factor 
VIII (FVIII) therapy, that is replacement of the absent endogenous FVIII 
by either plasma‐derived (pdFVIII) or recombinant FVIII (rFVIII).1 As un-
derdosing of exogenous FVIII may result in insufficient FVIII cover and 
increase patients’ bleeding risk, accurate assignment of the potency of 
FVIII concentrates is paramount. Likewise, accurate measurement of 
FVIII activity (FVIII:C) in plasma during treatment is essential for moni-
toring FVIII:C trough levels, assessment of FVIII pharmacokinetics and 
perioperative management of patients with haemophilia A.2
FVIII:C in patients receiving FVIII replacement therapy can be 
measured by either one‐stage or chromogenic substrate assays 
(OSAs and CSAs, respectively). The OSA is based on a modified 
activated partial thromboplastin time (aPTT) assay that is cal-
ibrated to a series of FVIII concentrations.3 The CSA employs a 
two‐stage design. In the first step, FVIII acts as a cofactor in the 
generation of activated coagulation factor X (FXa). The amount of 
FXa reflects the amount of FVIII in the sample and is determined 
by measuring the extent of FXa‐mediated hydrolysis of a chromo-
genic substrate.2,4
While the number of commercially available CSAs is relatively 
small, a large number of different aPTT reagents are available.5 This 
can lead to considerable variation in FVIII:C results, as OSA results 
are affected by the choice of phospholipid6 and surface activator/
aPTT reagent,7,8 as well as by the von Willebrand factor content of 
the FVIII‐deficient plasma.9 These variations are typically observed 
with rFVIII concentrates6,9 or modified FVIII products,7,8 but not nor-
mally with pdFVIII concentrates.6,9 Inter‐reagent variability is lower 
for CSAs, which represent the reference method of the European 
Pharmacopoeia for the potency assignment of products used for 
FVIII replacement therapy.10 However, the majority of laboratories 
use OSAs for monitoring in the clinical setting.11
Discrepancies between FVIII:C determined by OSAs and CSAs 
have been observed for rFVIII concentrates, with CSA:OSA ratios 
typically between 1.1 and 1.3.2 However, for ReFacto®, a B‐domain‐
deleted (BDD) rFVIII, OSA results were found to be 20%‐50% lower 
than those obtained with the CSA.6,12 The use of a product‐specific 
reference standard (reference laboratory standard, RLS) reduced this 
discrepancy and allowed for more accurate estimates using the OSA.13 
FVIII:C results for Afstyla®, a single‐chain BDD rFVIII, were approxi-
mately 50% lower with OSAs than with CSAs.14 In light of these obser-
vations, the factor VIII and factor IX Subcommittee of the Scientific and 
Standardisation Committee of the International Society on Thrombosis 
and Haemostasis (SSC/ISTH) recommends full characterization of be-
haviour in both the OSA and CSA for any new FVIII product.15
Nuwiq® (simoctocog alfa, human‐cl rhFVIII; Octapharma) is a 
fourth‐generation BDD rFVIII16 produced in a human cell line with 
human‐like post‐translational protein processing and without chem-
ical modification or fusion to any other protein.17,18 Nuwiq® is ef-
fective in the prevention and treatment of bleeds and for bleeding 
management during surgery in adults and children with haemophilia 
A19-21 and has demonstrated low immunogenicity in previously un-
treated patients.22
The aim of this field study was to assess whether Nuwiq® ac-
tivity can be accurately measured with a variety of OSAs and CSAs 
used in routine laboratory practice.
2  | METHODS
2.1 | Questionnaire
All participating laboratories completed a questionnaire to docu-
ment in‐house standard procedures for all assays routinely used, in-
cluding information on analysers, reagents, standards, dilutions and 
calibration techniques.
Results: Forty‐nine laboratories from 9 countries provided results. Mean absolute 
FVIII:C was comparable for both products at all concentrations with both OSA and 
CSA, with interproduct ratios (Nuwiq®:Advate®) of 1.02‐1.13. Mean recoveries 
ranged from 97% to 191% for Nuwiq®, and from 93% to 172% for Advate®, with 
higher recoveries at lower concentrations. Subgroup analyses by OSA and CSA rea-
gents showed minor variations depending on reagents, but no marked differences 
between the two products. CSA:OSA ratios based on overall means ranged from 0.99 
to 1.17 for Nuwiq® and from 1.01 to 1.17 for Advate®.
Conclusions: Both OSAs and CSAs are suitable for the measurement of FVIII:C of 
Nuwiq® in routine laboratory practice, without the need for a product‐specific refer-
ence standard.
K E Y W O R D S
coagulation factor VIII, Nuwiq®, human‐cl rhFVIII, one‐stage assay, chromogenic assay, field 
study
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2.2 | Sample preparation
Samples were prepared centrally by spiking congenital FVIII‐deficient 
plasma (Helena Biosciences) with Nuwiq® or Advate® at 4 concentra-
tions (1, 5, 30 and 100 international units [IU]/dL) based on nominal 
potencies determined by a CSA. SSC/ISTH Secondary Coagulation 
Standard Lot #4 (NIBSC code: SSCLOT4) was provided in lyophilized 
form. Samples were shipped frozen on dry ice. Each laboratory re-
ceived triplicate aliquots of each sample. Laboratories were blinded 
as to the identity of the concentrates and the target concentrations.
Advate®, a full‐length rFVIII of hamster cell line origin, was cho-
sen as a comparator as it was the most widely used rFVIII at the time 
the study was conceived, and it has been used as a comparator in 
field studies with other rFVIII products.7,14,23‐26
2.3 | Performance of assays
Participating laboratories were asked to determine FVIII:C on 
three separate days by means of whichever assay(s) they used rou-
tinely, following their standard procedures and using their in‐house 
equipment. Results were reported as final calculated activities.
2.4 | Data analysis
All questionnaires and FVIII:C data were submitted to a central process-
ing site that reviewed, edited and compiled the data. Compilation records 
were checked against the source files for 100% accuracy. In case of miss-
ing or implausible data, laboratories were contacted for clarification.
Statistical analysis was descriptive and performed by Ergomed 
CDS, Cologne, Germany using SAS version 9.3 (SAS Institute). 
Parameters analysed included absolute FVIII:C, relative recovery 
and inter‐ and intralaboratory coefficients of variation (CV). Values 
were calculated separately for OSAs and CSAs. Recovery was cal-
culated as absolute FVIII:C measured divided by the target con-
centration and expressed as a percentage of the target. Sensitivity 
analyses were performed to assess the impact of specific analysers, 
reagents or calibration methods on FVIII:C results. The CSA:OSA 
ratio was determined based on both the overall mean values and 
on the individual ratios for all laboratories performing both assays.
For all analyses, except intralaboratory precision, one mean value 
per sample, assay and laboratory was calculated from the triplicate 
results provided. Intralaboratory precision was determined based on 
the three results for each sample.
Outlier detection was performed based on robust regression di-
agnostics with a cut‐off equal to four times the mean.
3  | RESULTS
3.1 | Participating laboratories
Of 59 laboratories invited, 50 agreed to participate in the study. One 
laboratory was subsequently excluded for logistical reasons and did 
not receive a study kit. The majority of participating laboratories were 
located in Europe (Austria [n = 2], Belgium [n = 3], France [n = 11], 
Germany [n = 18], the Netherlands [n = 2], Switzerland [n = 6] and the 
UK [n = 5]), one was in Saudi Arabia and one in the USA.
3.2 | Methodologies used
Most laboratories (40/49; 81.6%) performed OSAs and CSAs, while 
8/49 (16.3%) performed the OSA only, and 1/49 (2.0%) performed 
the CSA only. As several laboratories performed more than one 
assay of a given type, the final data set consisted of 51 OSAs and 
43 CSAs.
The most common aPTT reagents for the OSA were SynthASil 
(Instrumentation Laboratory; n = 12), Pathromtin SL (Siemens; 
n = 11), C.K. Prest (Stago; n = 8) and Actin FS (Siemens; n = 8). The 
most frequently used platforms were ACL TOP (Instrumentation 
Laboratory; n = 16), BCS/BCS XP (Siemens; n = 13) and STA/STA R 
(Stago; n = 11). For the majority of OSAs, immunodepleted FVIII‐de-
ficient plasma (n = 46) and commercial calibrators (n = 47) were em-
ployed. Single calibration curves (median number of points 8; range 
6‐11) and dual calibration curves (median number of points 12; range 
8‐13) were used in 27 and 19 assay set‐ups, respectively. Most labo-
ratories (31/48; 64.6%) performed OSAs 3‐5 times per week.
For the CSA, the most common kits were Biophen FVIII:C 
(Hyphen BioMed; n = 20), factor VIII chromogenic assay (Siemens; 
n = 12) and Coamatic Factor VIII (Chromogenix; n = 5). The most 
frequently used platforms were BCS/BCS XP (Siemens; n = 15) and 
those from the ACL/ACL TOP (Instrumentation Laboratory; n = 10) 
and STA/STA R families (Stago; n = 10). Almost all laboratories em-
ployed commercial calibrators; dual and single calibration curves 
were used in 23 and 19 cases, with a median (range) number of 10 
(8‐17) and 6 (4‐9) points, respectively. Most laboratories (22/41; 
53.7%) performed CSAs 1‐3 times per month.
3.3 | Activity results
3.3.1 | Absolute FVIII:C and mean recovery
Mean absolute FVIII:C values were comparable for Nuwiq® and 
Advate® at all concentrations for both OSAs and CSAs (Table 1). The 
interproduct ratios (Nuwiq®:Advate®) based on overall mean FVIII:C 
ranged from 1.03 to 1.13 for the OSAs and from 1.02 to 1.11 for the 
CSAs. Mean recoveries in the OSA ranged from 97.3% to 183.8% for 
Nuwiq® and from 92.7% to 161.3% for Advate®; in the CSA, ranges 
were 112.4% to 190.8% for Nuwiq® and 108.5% to 172.0% for 
Advate®. For both OSAs and CSAs, higher recoveries were observed 
at lower concentrations. All reported recoveries for the SSC/ISTH 
standard were within 100 ± 25% (Table 1).
3.3.2 | Distribution of recovery
Figure 1 shows the distribution of recovery values for the OSAs 
and CSAs. Results were comparable for Nuwiq® and Advate® at all 
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concentrations. As observed for the mean values, median recovery 
decreased with increasing concentrations for both products.
3.3.3 | Inter‐ and intralaboratory precision
In accordance with the distribution patterns, interlaboratory CVs 
were high for low concentrations and decreased with increas-
ing potency (Table 2). For the OSA, they were 44.2% and 41.8% 
for the 1 IU/dL samples and 15.9% and 11.8% for the 100 IU/
dL samples for Nuwiq® and Advate®, respectively. For the CSA, 
values were 53.5% and 55.5% for the 1 IU/dL samples and 9.8% 
and 8.6% for the 100 IU/dL samples for Nuwiq® and Advate®, 
respectively.
Mean intralaboratory CVs were lower overall and tended to be 
higher at lower concentrations. Values for the OSA ranged from 
5.6% to 11.2% for Nuwiq® and from 4.8% to 12.7% for Advate®. For 
the CSA, ranges were 6.0% to 17.5% for Nuwiq® and 4.8% to 19.2% 
for Advate®.
A re‐calculation of inter‐ and intralaboratory CVs excluding out-
liers led to reductions for most values. The differences were mostly 
minor for intralaboratory CVs, whereas several interlaboratory CVs 
decreased by 30% or more of their initial value (Table 2), indicating 
the substantial effect of outliers on these values.
3.3.4 | Analyses by reagents
An analysis of FVIII:C recovery by aPTT reagent showed nearly 
twofold differences in mean recovery between reagents for the 
1 IU/dL samples; however, standard deviations and ranges were 
large (Figure 2). Comparable patterns were observed for Nuwiq® 
and Advate®, with the highest recoveries for SynthASil and C.K. 
Prest and the lowest recoveries with Pathromtin. Inter‐reagent 
differences decreased with increasing concentrations and were al-
most non‐existent for the 100 IU/dL samples. Similar results were 
obtained when the recoveries were analysed by activator (Table 
S1).
Figure 3 presents CSA results by assay kit. Mean recoveries dif-
fered slightly for the 1 IU/dL samples, with the factor VIII chromo-
genic assay kit showing the highest recovery for both products, and 
were similar for the 30 and 100 IU/dL samples.
For both subgroup analyses, results for median recoveries were 
comparable to those for the means (data not shown).
3.3.5 | Analyses by instruments
FVIII:C recovery by instrument for the OSA is displayed in Figure S1. 
As in the analysis by aPTT reagent, differences of nearly twofold in 
mean recovery were observed for the 1 IU/dL samples, with higher 
recoveries with ACL TOP and STA/STA R and lower recoveries with 
BCS/BCS XP. Patterns were comparable for Nuwiq® and Advate®, 
and differences diminished with increasing concentrations.
CSA results by instrument showed a much lower degree of vari-
ability even at low sample concentrations (Figure S2), with a tendency T
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towards higher recoveries with STA/STA R, but differences in mean 
recovery were small compared with the standard deviations.
3.3.6 | CSA:OSA ratios
CSA:OSA ratios based on the overall means ranged from 0.99 to 1.17 
for Nuwiq® and from 1.01 to 1.17 for Advate®. When ratios were 
calculated based on the mean of individual ratios from laboratories 
performing both assays, results ranged from 1.05 to 1.19 for Nuwiq® 
and from 1.06 to 1.25 for Advate®. In both cases, there were no 
concentration‐dependent trends (Table 3).
4  | DISCUSSION
This comparative international field study examined FVIII:C results 
obtained for simulated postinfusion samples of Nuwiq®, a BDD 
rFVIII produced in a human cell line, and Advate®, a full‐length rFVIII 
produced in a hamster cell line, using a broad range of OSAs and 
CSAs in routine laboratory practice. The data show comparable ac-
curacy and precision for both products across a range of concentra-
tions and assay reagents for both assays, with CSA:OSA ratios below 
1.3 in all cases.
The observed ranges in FVIII:C results are large for both prod-
ucts, particularly at low concentrations. The results were similar for 
Advate® and Nuwiq®, which suggests that the variability is not re-
lated to differences in the products, but rather to methodological 
differences between the assays or to differences between individ-
ual laboratories. The greater variability in values at lower concen-
trations has also been observed in previous field studies with other 
rFVIII products,23-26 with measured values more than twice as high 
as expected for individual samples at the lowest concentrations as-
sayed.14,23,26 Of note, the lowest concentration used in this study, 
1 IU/dL, is lower than that reported in previous studies, which gen-
erally ranged from 3 to 5 IU/dL 14,24‐26 and was even 20 IU/dL in one 
case.13
For the OSA, high variability of assay results and overestimation 
of FVIII:C at low concentrations have been described previously.11,27 
F I G U R E  1   Distribution of recovery values as determined by OSAs and CSAs. Results from one of the 51 OSAs were excluded due to a 
calculation error affecting all reported FVIII:C values; distributions are therefore based on n = 50. CSA, chromogenic assay; IU, international 
unit; OSA, one‐stage assay. Scatter plots for Nuwiq® and Advate® 1 IU/dL (A), 5 IU/dL (B), 30 IU dL (C) and 100 IU/dL (D) samples. Open 
circles: individual values, solid circle: mean, solid lines: first and third quartile, dashed line: median
(A) (B)
(C) (D)
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The CSA is generally assumed to be more sensitive at low concen-
trations.27 However, results from previous field studies are inconsis-
tent,25,26 and recent data from proficiency testing indicate that both 
OSAs and CSAs show high variability at low concentrations.28 It has 
been speculated that high variability at low target concentrations 
in the CSA may be due to the absence of very low concentration 
samples in calibration curves,25 and in fact, according to the ques-
tionnaire data, the lowest concentration used for calibration was 
≥2.5 IU/dL for almost one‐third of CSAs in this study (data not 
shown). Independently of this, it is important to note that for samples 
TA B L E  2   Inter‐ and intralaboratory precision
Product
Target concentration 
(IU/dL)
OSA (n = 50)a CSA (n = 43)
Interlaboratory CV (%)
Mean intralaboratory 
CV (%)b Interlaboratory CV (%)
Mean intralabo‐
ratory CV (%)b
Nuwiq® 1 44.2c 11.2c/10.3d 53.5c/45.7d 17.5c/12.9d
5 42.9/22.7d 7.9/7.2d 35.1c/24.7d 12.3c/10.8d
30 34.9/14.4d 5.6/5.2d 10.8/9.2d 6.1
100 15.9/11.7d 5.7/5.2d 9.8 6.0/4.6d
Advate® 1 41.8c 12.7c/11.7d 55.5c/47.7d 19.2c/14.5d
5 26.7 8.9 32.0c/23.37d 11.9c/7.7d
30 17.6/11.8d 5.2/4.3d 10.6 4.8/4.5d
100 11.8/9.2d 4.8/4.3d 8.6 5.2
Standard 88 8.5 5.1/3.9d 7.4 4.1
Note: Data are shown as CVs calculated based on all available data/CVs calculated excluding outliers (where different; otherwise not indicated).
Abbreviations: CSA, chromogenic assay; CV, coefficient of variation; IU, international unit; OSA, one‐stage assay.
aResults from one of the 51 assays were excluded due to a calculation error affecting all reported FVIII:C values. 
bCV calculated based on triplicate measurements per sample, method and laboratory. 
cSome values were excluded from the analysis because exact FVIII:C values were not provided; therefore, n is less than the n listed in the column title 
(OSA: n = 48 for Nuwiq® 1 IU/dL and n = 47 for Advate® 1 IU/dL; CSA: n = 37 for both 1 IU/dL samples for interlaboratory CVs, n = 36 for both 1 IU/
dL samples for intralaboratory CVs, and n = 40 for both 5 IU/dL samples). 
dDue to exclusion of outliers, n is less than the n for the calculation based on all available values (OSA: n = 49 for both 30 IU/dL and 100 IU/dL 
samples and n = 48 for Nuwiq® 5 IU/dL for interlaboratory CVs; n = 49 for Nuwiq® 5 IU/dL and 30 IU/dL and for both 100 IU/dL samples, n = 47 for 
Nuwiq® 1 IU/dL and Advate® 30 IU/dL and n = 46 for Advate® 1 IU/dL for intralaboratory CVs; CSA: n = 40 for Nuwiq® 30 IU/dL, n = 38 for both 
5 IU/dL samples and n = 36 for both 1 IU/dL samples for interlaboratory CVs; n = 42 for Advate® 30 IU/dL, n = 41 for Nuwiq® 100 IU/dL, n = 38 for 
Nuwiq® 5 IU/dL, n = 35 for Advate® 5 IU/dL and n = 34 for both 1 IU/dL samples for intralaboratory CVs). 
F I G U R E  2   Target recovery (%) as determined by OSAs, analysed by aPTT reagent. Data are presented as mean ± SD (range). Only aPTT 
reagents used by at least five laboratories were included in the analysis. Results from one of the 51 assays were excluded due to an obvious 
calculation error affecting all reported FVIII:C values. aPTT, activated partial thromboplastin time; IU, international unit; OSA, one‐stage 
assay; SD, standard deviation. Some values were excluded from the analysis because no exact FVIII:C values were provided; therefore, for 
the columns with footnotes, n is less than the n listed in the legend: bn = 7; cn = 6; dn = 4
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with a concentration as low as 1 IU/dL, large percentage differences 
correspond to very small differences in absolute FVIII:C values.
To decrease variation in FVIII:C, particularly when measuring 
high‐purity FVIII concentrates, recommendations for the stan-
dardization of assays have been issued.29 These include the use of 
FVIII‐deficient plasma for predilution of samples and the use of 1% 
of albumin in all assay buffers. However, in our study using the as-
says routinely employed in the participating laboratories, diluents 
other than FVIII‐deficient plasma were used for predilution of sam-
ples in 46 of the 50 evaluated OSAs, and buffers without albumin 
were used for sample preparation in 15 of the 43 CSAs. For the 
OSA, it is hard to assess the effect of diluents other than FVIII‐de-
ficient plasma on assay results in our study as only two laboratories 
confirmed the use of FVIII‐deficient plasma (the other two did not 
provide any information). However, published data demonstrate that 
diluting all samples and standards in FVIII‐deficient plasma improves 
the accuracy of the OSA by decreasing the overestimation for sam-
ples with low FVIII:C.30 Regarding the CSA results obtained in this 
study, the ranges of actual FVIII:C values for samples with low con-
centrations (ie 1 and 5 IU/dL) were indeed wider for assays in which 
buffers without albumin were used, compared with those employing 
albumin‐containing buffers (data not shown).
The interlaboratory and intralaboratory precision for Advate® 
in our study were similar to previously reported values. Published 
results for interlaboratory CVs range from 10% to 34%24 for the 
OSA and from 5%26 to 51%23 for the CSA, with the highest values 
consistently observed for the lowest concentrations. High interlab-
oratory CVs at low sample concentrations have also been reported 
in proficiency testing, with values of up to approximately 120% for 
samples with concentrations below 20 IU/dL.28,31 For intralabora-
tory precision, previously reported values for Advate® range from 
5%23 to 13%25 for the OSA and from 2%23 to 15%25 for the CSA.
Our study showed inter‐reagent differences in FVIII:C of approx-
imately twofold for both the OSA and the CSA at low concentra-
tions. Differences of a similar magnitude between different aPTT 
reagents have been reported in a study using low concentrations 
of Afstyla®.32 Another study reported differences between aPTT 
reagents even at higher FVIII:C, with higher values observed for 
SynthASil vs Actin FS,33 consistent with our results. Analyses by CSA 
reagents did not show any major inter‐reagent differences but were 
exclusively based on samples with FVIII:C of >20 IU/dL,33-35 in which 
marked differences are less likely to be found. In the present study, 
differences were less pronounced in the 30 and 100 IU/dL samples.
The influence of other methodological parameters has rarely 
been studied. A possible minor impact of the analyser on FVIII:C re-
sults has been reported in two small studies,34,35 with one of them 
showing a tendency towards higher recovery with ACL TOP com-
pared with Sysmex for the OSA,35 in line with our findings.
CSA:OSA ratios were comparable for both products and below 
or within the expected range of 1.1 to 1.3,2 indicating that the dele-
tion of the B‐domain per se does not result in CSA‐OSA discrepan-
cies, which confirms observations from other field studies involving 
BDD rFVIII.24,26
In previous studies, usually only a low proportion of laboratories 
(one‐third or below) provided results for CSAs.7,14,23‐26 The present 
field study is the first such study with over 80% of laboratories rou-
tinely using CSAs and providing corresponding FVIII:C results.
This study has some limitations. First, although samples mim-
icked postinfusion samples from FVIII‐deficient patients as closely 
as possible, it cannot be excluded that actual patient postinfu-
sion samples may behave differently.27 However, it was recently 
demonstrated for Advate® that both types of samples yield com-
parable results in OSAs and CSAs.35 Second, only one lot of each 
product and of FVIII‐deficient plasma was used to prepare the 
samples, and as most laboratories performed the three assay runs 
within 2 weeks, the use of different reagent lots is unlikely. Third, 
the influence of some assay parameters was not analysed, because 
certain reagents were either not used in the study (eg FVIII‐de-
ficient plasma containing low levels of von Willebrand factor) or 
were used by one or two laboratories only, precluding reliable sta-
tistical analysis.
In conclusion, comparable FVIII:C results were obtained for 
Nuwiq® and Advate® across a range of concentrations and using a 
variety of OSA and CSA reagents. Therefore, both OSAs and CSAs 
F I G U R E  3   Target recovery (%) as 
determined by CSAs, analysed by assay 
kit. Data are presented as mean ± SD 
(range). Only kits used by at least five 
laboratories were included in the analysis. 
CSA, chromogenic assay; IU, international 
unit; SD, standard deviation. Some values 
were excluded from the analysis because 
no exact FVIII:C values were provided; 
therefore, for the columns with footnotes, 
n is less than the n listed in the legend: 
an = 18; bn = 19; cn = 9; dn = 11
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are suitable to determine FVIII:C of Nuwiq® in routine laboratory 
practice, without the need for a product‐specific reference standard.
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